In a June 12 conference at UW-Madison, researchers gathered from across the U.S. and abroad to discuss the latest progress on TDP-43 biomarkers. In all, 74 people attended in person, and 727 virtually ...

Do you know a conference you think we should list? Let us know by sending us an email with the details to [email protected] ...

Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

As reported in 1994, the original SOD1-G93A strain, designated G1, expressed approximately 18 copies of human SOD1, randomly inserted into the genome (Gurney et al., 1994). An unequal crossover event ...

Sensory Stimulation Systems, and GENUS, refer to a noninvasive procedure, i.e., a "digital therapeutic," being developed by Cognito Therapeutics. The company developed a wearable GammaSense ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

If enhancing memory with light and sound seems futuristic, then welcome to the future. Or so some scientists say. Results from four early stage clinical trials on mild Alzheimer’s disease were ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

In the two weeks since the Food and Drug Administration approved a license for Biogen’s Alzheimer’s antibody aducanumab, marketed as Aduhelm, controversy over the decision has continued to build.

After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...

Purported miracle medicines have always been with us. In the 1800s, traveling salesmen hawked cure-all elixirs. Nowadays, companies peddle myriad supplements on the internet, often with spurious ...

Studies aim to validate Alzheimer's disease blood tests against gold standard biomarkers in primary care. Scientists ask how best to incorporate AD blood tests into existing healthcare systems. Some ...